Clinical Trial Update: Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CG0070 in combination with pembrolizumab for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• CG0070
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: CG Oncology, Inc. | Conditions: Non Muscle Invasive Bladder Cancer | Phase 2 | Status: COMPLETED